Stockreport

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update [Yahoo! Finance]

Roivant Sciences Ltd.  (ROIV) 
PDF Once-daily brepocitinib produced the best Treatment Failure rates observed to date among studies in active non-infectious uveitis (NIU), supporting initiation of a pivo [Read more]